Tech Company Financing Transactions
R1 Therapeutics Funding Round
R1 Therapeutics, based in London, received $77.5 million from Abingworth, DaVita Venture Group and F-Prime Capital.
Transaction Overview
Company Name
Announced On
3/17/2026
Transaction Type
Venture Equity
Amount
$77,500,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to accelerate its global development program of AP306 in partnership with Alebund, including a Phase 2b study planned to start later this year.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
8 Devonshire Square, The Spice Building
London, EC2M 4PL
UK
London, EC2M 4PL
UK
Phone
Undisclosed
Website
Email Address
Overview
R1 Therapeutics is developing innovative first-in-class therapies for patients with kidney disease, starting with lead asset AP306 for the treatment of hyperphosphatemia in patients with chronic kidney disease. Our objective is to deliver meaningful change for patients who have long been underserved. Hyperphosphatemia patients have relied on variations of the same phosphate binding treatment approach for the last 60 years. Existing therapies require patients to take up to 9--15 pills a day, are not well tolerated and still leave more than 40% of U.S. patients unable to achieve normal phosphate levels.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Krishna Polu
Browse more venture capital transactions:
Prev: 3/17/2026: Steward venture capital transaction
Next: 3/18/2026: Beautiful.AI venture capital transaction
Share this article
About Our VC Transactions Data
Our team works diligently to record tech company VC transactions. VC investment data records on this site come from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs